KR920012040A - 신규의 디히드로-이소퀴놀린 유도체 - Google Patents

신규의 디히드로-이소퀴놀린 유도체 Download PDF

Info

Publication number
KR920012040A
KR920012040A KR1019910022728A KR910022728A KR920012040A KR 920012040 A KR920012040 A KR 920012040A KR 1019910022728 A KR1019910022728 A KR 1019910022728A KR 910022728 A KR910022728 A KR 910022728A KR 920012040 A KR920012040 A KR 920012040A
Authority
KR
South Korea
Prior art keywords
compound
ester
acid addition
subject
pharmaceutically acceptable
Prior art date
Application number
KR1019910022728A
Other languages
English (en)
Inventor
레토 네프 닥터.
Original Assignee
진 크래머, 한스 루돌프 하우스
산도즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 진 크래머, 한스 루돌프 하우스, 산도즈 리미티드 filed Critical 진 크래머, 한스 루돌프 하우스
Publication of KR920012040A publication Critical patent/KR920012040A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Abstract

내용 없음

Description

신규의 디히드로-이소퀴놀린 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 하기식(Ⅰ)의 화합물 또는 그들의 생리적으로 가수분해 및 수용 가능한 에스테르 또는 상기 화합물 또는 에스테르의 산부가염.
    상기식에서, R1내지 R4는 각각 독립적으로 C1-4알콕시이다.
  2. 제1항에 있어서, 일반식(Ⅰ)에서 R1내지 R4는 각각 메톡시인 화합물, 또는 그들의 생리적으로 가수분해 및 수용 가능한 에스테르 또는 상기 화합물 또는 에스테르의 산부가염.
  3. 제1항에 있어서, [3S]거울상 이성질체 형태인 화합물 또는 그들의 생리적으로 가수분해 및 수용 가능한 에스테르 또는 상기 화합물 또는 에스테르의 산부가염.
  4. 제1항에 있어서, [3S]3,4-디히드로-6,7-디메톡시-1-(3,5-디메톡시-페닐)-3-히드록시메틸-이소퀴놀린인 화합물, 또는 그의 산부가염.
  5. 제1항에 있어서, [3S]3,4-디히드로-1-(3,5-디이소프로필옥시-페닐)-3-히드록시-메틸-6-이소프로필옥시-7-메톡시-이소퀴놀린인 화합물, 또는 그의 산부가염.
  6. 제1항의 화합물 또는 에스테르 또는 상기 화합물 또는 에스테르의 약학적 허용 가능 산부가염과, 이들의 약학적 허용 가능 희석제 또는 담체를 함께 포함하는 약학 조성물.
  7. 제1항의 화합물 또는 에스테르 또는 상기 화합물 또는 에스테르의 약학적 허용 가능 산부가염의 유효량을 피검자에게 투여하는 단계를 포함하는 피검자의 필요에 따른 기관지 확장 방법.
  8. 제1항의 화합물 또는 에스테르 또는 상기 화합물 또는 에스테르의 약학적 허용 가능 산부가염의 유효량을 피검자에게 투여하는 단계를 포함하는 피검자의 필요에 따른 기동 과잉 작용의 억제 또는 개선 방법.
  9. 제1항의 화합물 또는 에스테르 또는 상기 화합물 또는 에스테르의 약학적 허용 가능 산부가염의 유효량을 피검자에게 투여하는 단계를 포함하는 피검자의 필요에 따른 폐쇄성 또는 염증성 기도 질환의 치료방법.
  10. 제1항의 화합물 또는 에스테르 또는 상기 화합물 또는 에스테르의 약학적 허용 가능 산부가염의 유효량을 피검자에게 투여하는 단계를 포함하는 피검자의 필요에 따른 천식의 치료 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910022728A 1990-12-13 1991-12-12 신규의 디히드로-이소퀴놀린 유도체 KR920012040A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9027055.4 1990-12-13
GB909027055A GB9027055D0 (en) 1990-12-13 1990-12-13 Organic compounds

Publications (1)

Publication Number Publication Date
KR920012040A true KR920012040A (ko) 1992-07-25

Family

ID=10686945

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910022728A KR920012040A (ko) 1990-12-13 1991-12-12 신규의 디히드로-이소퀴놀린 유도체

Country Status (25)

Country Link
US (1) US5177085A (ko)
EP (1) EP0490823B1 (ko)
JP (1) JPH0764820B2 (ko)
KR (1) KR920012040A (ko)
AT (1) ATE145201T1 (ko)
AU (1) AU643575B2 (ko)
CA (1) CA2057524A1 (ko)
CZ (1) CZ281669B6 (ko)
DE (1) DE69123124T2 (ko)
DK (1) DK0490823T3 (ko)
ES (1) ES2093694T3 (ko)
FI (1) FI915844A (ko)
GB (1) GB9027055D0 (ko)
GR (1) GR3022034T3 (ko)
HU (1) HUT61729A (ko)
IE (1) IE914325A1 (ko)
IL (1) IL100328A (ko)
MX (1) MX9102502A (ko)
MY (1) MY129941A (ko)
NZ (1) NZ240936A (ko)
PL (1) PL168329B1 (ko)
PT (1) PT99775B (ko)
RU (1) RU2060992C1 (ko)
TW (1) TW201736B (ko)
ZA (1) ZA919858B (ko)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9212673D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
GB9226830D0 (en) * 1992-12-23 1993-02-17 Celltech Ltd Chemical compounds
US5622977A (en) * 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9322828D0 (en) * 1993-11-05 1993-12-22 Sandoz Ltd Organic compounds
GB9326173D0 (en) * 1993-12-22 1994-02-23 Celltech Ltd Chemical compounds and process
WO1995017399A1 (en) * 1993-12-22 1995-06-29 Celltech Therapeutics Limited Trisubstituted phenyl derivatives, processes for their preparation and their use as phosphodiesterase (type iv) inhibitors
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412571D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) * 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
US5922751A (en) * 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
ES2171191T3 (es) * 1994-08-22 2002-09-01 Mitsubishi Pharma Corp Compuesto de benceno y uso medicinal del mismo.
US5948820A (en) 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
DE69531555T2 (de) * 1994-12-13 2004-06-17 Euroceltique S.A. Dreifachsubstituierte thioxanthine
US6025361A (en) * 1994-12-13 2000-02-15 Euro-Celtique, S.A. Trisubstituted thioxanthines
US6268373B1 (en) * 1995-06-07 2001-07-31 Euro-Celtique S.A. Trisubstituted thioxanthines
GB9523267D0 (en) * 1995-11-14 1996-01-17 Sandoz Ltd Organic compounds
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9526243D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
AU2593997A (en) * 1996-03-21 1997-10-10 Trustees Of Columbia University In The City Of New York, The Craf1 (traf-3) isoforms and uses thereof
US6075016A (en) * 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
WO1998017636A1 (en) * 1996-10-22 1998-04-30 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
ID19155A (id) * 1996-12-13 1998-06-18 Tanabe Seiyaku Co Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya
WO1998028281A1 (en) 1996-12-23 1998-07-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
AU6230098A (en) * 1997-02-27 1998-09-18 Tanabe Seiyaku Co., Ltd. Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
CZ293725B6 (cs) 1997-07-25 2004-07-14 Altana Pharma Ag Tetrazolové deriváty
JP2001518468A (ja) * 1997-09-30 2001-10-16 モレキュラー デザインズ インターナショナル，インコーポレイテッド β３アドレナリン受容体拮抗薬、拮抗薬合成物およびこれらの応用方法
IT1296985B1 (it) 1997-12-19 1999-08-03 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
IT1302677B1 (it) * 1998-10-15 2000-09-29 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
PL200923B1 (pl) 1999-08-21 2009-02-27 Nycomed Gmbh Lek zawierający inhibitor PDE w połączeniu z agonistą receptoraß₂ -adrenergicznego oraz zastosowanie połączenia roflumilastu i salmeterolu
GB9924862D0 (en) * 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
CA2404226A1 (en) * 2000-03-23 2001-09-27 Takeda Chemical Industries, Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
WO2002040449A1 (en) * 2000-11-14 2002-05-23 Altana Pharma Ag Dihydroisoquinolines as novel phosphodiesterase inhibitors
AU2954102A (en) 2000-11-14 2002-05-27 Byk Gulden Lomberg Chem Fab (dihydro)isoquinoline derivatives as phosphodiesterase inhibitors
US6593341B2 (en) 2001-03-29 2003-07-15 Molecular Design International, Inc. β3-adrenoreceptor agonists, agonist compositions and methods of making and using the same
ES2320204T3 (es) * 2001-05-29 2009-05-20 Bayer Schering Pharma Aktiengesellschaft Pirimidinas inhibidoras de cdk, su preparacion y su utilizacion como medicamentos.
BR0306811A (pt) * 2002-01-11 2004-10-26 Sankyo Co Composto, éster farmacologicamente aceitável do mesmo, composição farmacêutica e métodos para prevenção ou tratamento de doenças autoimunes, da artrite reumatóide e da rejeição causada pelo transplante de vários órgãos em um mamìfero
US7745180B2 (en) * 2002-04-24 2010-06-29 Hitachi Chemical Co., Ltd. Device and method for high-throughput quantification of mRNA from whole blood
WO2004018465A2 (en) * 2002-08-17 2004-03-04 Altana Pharma Ag Benzonaphthyridines with pde 3/4 inhibiting activity
JP2005537312A (ja) * 2002-08-17 2005-12-08 アルタナ　ファルマ　アクチエンゲゼルシャフト 新規のフェナントリジン
WO2004019945A1 (en) 2002-08-29 2004-03-11 Altana Pharma Ag 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
AU2003255493B8 (en) 2002-08-29 2009-03-26 Takeda Gmbh 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors
US6596734B1 (en) 2002-10-11 2003-07-22 Molecular Design International, Inc. Tetrahydroisoquinoline compounds for use as β3-adrenoreceptor agonists
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EA200501548A1 (ru) 2003-04-01 2006-02-24 Апплайд Резеч Системз Арс Холдинг Н.В. Ингибиторы фосфодиэстераз при бесплодии
EP1720835B1 (en) 2004-02-18 2012-12-12 Nycomed GmbH Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (pde) 4 inhibitors
CN1921847B (zh) 2004-02-24 2010-06-16 三共株式会社 氨基醇化合物
CN102295634A (zh) 2004-03-03 2011-12-28 尼科梅德有限责任公司 新的羟基-6-杂芳基菲啶及其作为pde4抑制剂的用途
PT1856093E (pt) 2005-03-02 2010-02-08 Nycomed Gmbh Sal hcl de (2r,4ar,10br)-6-(2,6-dimetoxipiridin-3-il)-9-etoxi- 8-metoxi-1,2,3,4,4a,10b-hexa-hidrofenantridin-2-ol
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012118972A2 (en) 2011-03-01 2012-09-07 Synegy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
EP3718557A3 (en) 2013-02-25 2020-10-21 Bausch Health Ireland Limited Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2913737A1 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
CA2920856A1 (en) 2013-08-09 2015-02-12 Ardelyx, Inc. Ph modulating compounds for inhibiting gastrointestinal phosphate uptake
EP3033082B1 (en) 2013-08-16 2021-06-16 Universiteit Maastricht Treatment of cognitive impairment with pde4 inhibitor
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1400425A (en) * 1971-09-22 1975-07-16 Rolland Sa A Substituted 3-hydroxymethyl-isoquinolines and derivatives
HU196758B (en) * 1986-05-21 1989-01-30 Gyogyszerkutato Intezet Process for production of 3-hidroxi-methil-quinolines and medical compositions containing them
CA1330560C (en) * 1986-05-21 1994-07-05 Maurits E. A. Vandewalle Di- and tetrahydroisoquinoline derivatives
GB8800397D0 (en) * 1988-01-08 1988-02-10 Sandoz Ltd Improvements in/relating to organic compounds

Also Published As

Publication number Publication date
NZ240936A (en) 1993-09-27
ATE145201T1 (de) 1996-11-15
EP0490823A1 (en) 1992-06-17
DE69123124T2 (de) 1997-05-15
PT99775B (pt) 1999-05-31
EP0490823B1 (en) 1996-11-13
DK0490823T3 (ko) 1997-02-17
DE69123124D1 (de) 1996-12-19
ES2093694T3 (es) 1997-01-01
CZ281669B6 (cs) 1996-12-11
US5177085A (en) 1993-01-05
JPH0764820B2 (ja) 1995-07-12
HU913760D0 (en) 1992-02-28
CA2057524A1 (en) 1992-06-14
HUT61729A (en) 1993-03-01
FI915844A (fi) 1992-06-14
PL168329B1 (pl) 1996-02-29
GR3022034T3 (en) 1997-03-31
AU8898591A (en) 1992-06-18
MX9102502A (es) 1992-06-01
RU2060992C1 (ru) 1996-05-27
CS375791A3 (en) 1992-06-17
AU643575B2 (en) 1993-11-18
ZA919858B (en) 1993-06-14
IL100328A (en) 1995-12-08
IL100328A0 (en) 1992-09-06
IE914325A1 (en) 1992-06-17
MY129941A (en) 2007-05-31
JPH04275276A (ja) 1992-09-30
TW201736B (ko) 1993-03-11
FI915844A0 (fi) 1991-12-11
GB9027055D0 (en) 1991-02-06
PL292738A1 (en) 1992-12-14
PT99775A (pt) 1992-11-30

Similar Documents

Publication Publication Date Title
KR920012040A (ko) 신규의 디히드로-이소퀴놀린 유도체
ES539446A0 (es) Un procedimiento para preparar un derivado de dihidropiridazinona
KR860700253A (ko) 메발로노락톤의 피라졸 동족체 및 이의 유도체, 이들의 제조방법 및 이들의 용도
MX11031A (es) Proceso para la preparacion de nuevas 1-fenil-3-naftaleniloxipropanaminas producto obtenido y composicion farmaceutica que lo incluye.
KR940006580A (ko) 질병을 치료하기 위한 치환된 사이클로헥산 유도체
KR890009962A (ko) 매뉴마이신 유도체, 이의 제조방법 및 용도
KR900016135A (ko) 피부 및 점막-상피의 질환 치료용 4-퀴놀린 카복실산 유도체
KR900018048A (ko) 환 치환된 2-아미노-1,2,3,4-테트라하이드로나프탈렌
KR890000395A (ko) 페놀, 유도체, 그의 제조방법 및 용도
KR890012942A (ko) 5-치환된 오르니틴 유도체
EP0207497A3 (en) Quinolonecarboxylic acid derivative and process for its preparation
GR3020271T3 (en) (Benzhydryloxyethylpiperidyl)aliphatic acid derivatives and their use in the treatment of allergies and asthma
KR830004320A (ko) 퀴나졸린 유도체의 제조방법
KR920002517A (ko) 칼모둘린 억제 특성을 갖는 벤즈히드릴 유도체 및 그의 제조방법
IE45178L (en) Phenothiazine derivatives
KR840006984A (ko) 새로운 약학적 화합물 및 이의 제조방법
KR930701408A (ko) 화학적 화합물
DE69720496D1 (en) Benzimidazolderivate
KR880013896A (ko) 벤조푸로[3,2-c]퀴놀린 화합물
KR850000415A (ko) 퀴나졸리논 유도체의 제조방법
KR890002168A (ko) 디하이드로-1,4-옥사지노[2,3-c]퀴놀린, 그의 제조방법 및 중간생성물 및 약제로서의 용도
ATE43594T1 (de) 3-alkoxy-2-(n-pyrrolidino)-n-pyridyl-n-furyl(od r thienyl)-methyl-propylamine, ihre herstellung und diese enthaltende pharmazeutische mittel.
KR920003970A (ko) 혈중 요산 함량의 강하 방법
IT1205640B (it) Nuovi composti ad attivita' antiinfiammatoria,procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
SE8205523D0 (sv) Antranilsyraestrar, forfarande for framstellning derav och farmaceutiska kompositioner som innehaller dem

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application